MX354965B - Metodo para mejorar la funcion del diafragma. - Google Patents

Metodo para mejorar la funcion del diafragma.

Info

Publication number
MX354965B
MX354965B MX2014011881A MX2014011881A MX354965B MX 354965 B MX354965 B MX 354965B MX 2014011881 A MX2014011881 A MX 2014011881A MX 2014011881 A MX2014011881 A MX 2014011881A MX 354965 B MX354965 B MX 354965B
Authority
MX
Mexico
Prior art keywords
methods
skeletal muscle
diaphragm
patient
function
Prior art date
Application number
MX2014011881A
Other languages
English (en)
Other versions
MX2014011881A (es
Inventor
Malik Fady
R Jasper Jeffrey
T Hwee Darren
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2014011881A publication Critical patent/MX2014011881A/es
Publication of MX354965B publication Critical patent/MX354965B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un activador de troponina de musculo esquelético para preparar un medicamento para usarse en un método para mejorar la función del diafragma en necesidad del mismo, que comprende administrar al paciente una cantidad efectiva de un activador del troponina de musculo esquelético; en donde el paciente sufre de una enfermedad o padecimiento seleccionado del grupo que consiste en trastornos respiratorios del sueño, atrofia diafragmática, debilidad o atrofia diafragmática inducida por la ventilación atrofia diafragmática inducida por esteroides, parálisis del hemidiafragma, hidropesía fetal, derrame pleural, intoxicación botulínica intoxicación por organofosfato, síndrome Guillain.barré, disfunción del nervio frénico, accidente cerebrovascular, asma, malformación de Arnold-Chiari, cuadriplejia, poliomielitis, siringomielia, comprensión tumoral, hiperinflación, idiopática, botulismo, consumo de drogas, deficiencia de ácido maltásico, esclerosis múltiple, insuficiencia cardíaca, atrofia muscular espinal (SMA), miastenia gravis, enfermedad pulmonar obstructiva crónica (COPD), distrofia muscular, neuropatía neurálgica, enfermedad crítica con polineuropatía plineuropatía desmielinizante inflamatoria crónica, enfermedad de Charcot-Marie-Tooth, síndrome de Lambert-Eaton, miositis y atrofia de desuso; y en donde el activador de troponina del músculo esquelético es seleccionado del grupo que consiste en compuestos de la Formula A y compuestos de la Formula B: y sales farmacéuticamente aceptables del mismo, en donde: R1 es alquenilo o alquinilo; R4 es hidrógeno; R2 se selecciona del grupo que consiste de 3-pentilo, 4-heptilo, 4-metil-1-morfolinopentan-2-ilo isobutilo, ciclohexilo, ciclopropilo, sec-butilo, ter-butilo, isopropilo, 1-hidroxibutan-2-ilo, tetrahidro-2Hpiran-4-ilo, 1-metoxibutan-2ilo, 1-aminobutan-2-ilo, y 1-morfolinobutan-2-ilo; siempre que R1 no sea hex-1-enilo. .
MX2014011881A 2012-04-02 2013-04-01 Metodo para mejorar la funcion del diafragma. MX354965B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
PCT/US2013/034824 WO2013151938A1 (en) 2012-04-02 2013-04-01 Methods for improving diaphragm function

Publications (2)

Publication Number Publication Date
MX2014011881A MX2014011881A (es) 2016-07-20
MX354965B true MX354965B (es) 2018-03-27

Family

ID=49300969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011881A MX354965B (es) 2012-04-02 2013-04-01 Metodo para mejorar la funcion del diafragma.

Country Status (15)

Country Link
US (2) US20150065525A1 (es)
EP (1) EP2834269A4 (es)
JP (3) JP6345645B2 (es)
KR (1) KR20160046693A (es)
CN (2) CN104379597A (es)
AU (2) AU2013243671B2 (es)
BR (1) BR112014024552A2 (es)
CA (1) CA2868507A1 (es)
EA (1) EA031183B1 (es)
HK (1) HK1206364A1 (es)
IL (2) IL234885A0 (es)
MX (1) MX354965B (es)
PH (1) PH12014502217A1 (es)
SG (2) SG10201701101YA (es)
WO (1) WO2013151938A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
CN104395458A (zh) * 2012-04-11 2015-03-04 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
HRP20220183T1 (hr) 2014-04-29 2022-04-29 Cytokinetics, Inc. Postupci smanjivanja propadanja vitalnog kapaciteta
RS60013B1 (sr) 2014-06-05 2020-04-30 Vertex Pharma Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
EP3192512B1 (en) * 2014-09-09 2019-08-14 Astellas Pharma Inc. Novel pharmaceutical composition for urinary incontinence prevention and/or treatment
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
MX2018009759A (es) 2016-02-12 2018-11-29 Astellas Pharma Inc Derivados de tetrahidroisoquinolina.
KR20190026902A (ko) 2016-07-14 2019-03-13 화이자 인코포레이티드 바닌-1 효소의 억제제로서의 신규 피리미딘 카르복스아미드
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
MX2023004745A (es) 2020-11-06 2023-05-10 Cytokinetics Inc 1,4-diazepanonas biciclicas y sus usos terapeuticos.
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CN1283793C (zh) * 2002-06-03 2006-11-08 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
WO2005014580A1 (en) * 2003-08-08 2005-02-17 Janssen Pharmaceutica, N.V. Pyridyl piperazinyl ureas
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
EP2995619B1 (en) * 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
KR20100044251A (ko) * 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos

Also Published As

Publication number Publication date
EP2834269A1 (en) 2015-02-11
AU2013243671A1 (en) 2014-10-16
EP2834269A4 (en) 2015-12-30
IL267876B (en) 2021-03-25
WO2013151938A1 (en) 2013-10-10
AU2017272286B2 (en) 2019-05-09
BR112014024552A2 (pt) 2017-09-19
CN108553467A (zh) 2018-09-21
IL267876A (en) 2019-09-26
AU2017272286A1 (en) 2018-01-04
HK1206364A1 (en) 2016-01-08
EA031183B1 (ru) 2018-11-30
PH12014502217A1 (en) 2015-01-12
IL234885A0 (en) 2014-12-31
EA201491605A1 (ru) 2015-03-31
CA2868507A1 (en) 2013-10-10
AU2013243671B2 (en) 2017-09-21
JP6345645B2 (ja) 2018-06-20
MX2014011881A (es) 2016-07-20
JP2018131460A (ja) 2018-08-23
US20150065525A1 (en) 2015-03-05
SG11201406270YA (en) 2014-10-30
CN104379597A (zh) 2015-02-25
KR20160046693A (ko) 2016-04-29
SG10201701101YA (en) 2017-04-27
US20170266192A1 (en) 2017-09-21
JP2015516957A (ja) 2015-06-18
JP2020147607A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
PH12014502217A1 (en) Methods for improving diaphragm function
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
PH12014502698B1 (en) Improved antagonist antibodies against gdf-8 and uses therefor
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201491666A1 (ru) Способы повышения устойчивости скелетных мышц к утомлению
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
JO3154B1 (ar) عوامل مضادة لـ trpv4
EA201390799A1 (ru) Триазолопиридины
MX2013004062A (es) Analogos de ciclosporina.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
EA201491609A1 (ru) Модуляторы x рецепторов печени
PH12014500990A1 (en) Methods for treating gout flares
NZ713129A (en) Oxprenolol compositions for treating cancer
AU2012388759A8 (en) Methods and compositions for hypotensive resuscitation
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
EA201590232A1 (ru) Животная модель болезни краббе
NZ718896A (en) Methods for improving diaphragm function
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CYTOKINETICS, INC.

FG Grant or registration